A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä
Blood-based biomarkers and traumatic brain injury-A clinical perspective
Tekijät: Posti Jussi P, Tenovuo Olli
Kustantaja: WILEY
Julkaisuvuosi: 2022
Journal: Acta Neurologica Scandinavica
Tietokannassa oleva lehden nimi: ACTA NEUROLOGICA SCANDINAVICA
Lehden akronyymi: ACTA NEUROL SCAND
Sivujen määrä: 11
ISSN: 0001-6314
DOI: https://doi.org/10.1111/ane.13620
Verkko-osoite: https://doi.org/10.1111/ane.13620
Tiivistelmä
Blood-based biomarkers are promising tools to complement clinical variables and imaging findings in the diagnosis, monitoring and outcome prediction of traumatic brain injury (TBI). Several promising biomarker candidates have been found for various clinical questions, but the translation of TBI biomarkers into clinical applications has been negligible. Measured biomarker levels are influenced by patient-related variables such as age, blood-brain barrier integrity and renal and liver function. It is not yet fully understood how biomarkers enter the bloodstream from the interstitial fluid of the brain. In addition, the diagnostic performance of TBI biomarkers is affected by sampling timing and analytical methods. In this focused review, the clinical aspects of glial fibrillary acidic protein, neurofilament light, S100 calcium-binding protein B, tau and ubiquitin C-terminal hydrolase-L1 are examined. Current findings and clinical caveats are addressed.
Blood-based biomarkers are promising tools to complement clinical variables and imaging findings in the diagnosis, monitoring and outcome prediction of traumatic brain injury (TBI). Several promising biomarker candidates have been found for various clinical questions, but the translation of TBI biomarkers into clinical applications has been negligible. Measured biomarker levels are influenced by patient-related variables such as age, blood-brain barrier integrity and renal and liver function. It is not yet fully understood how biomarkers enter the bloodstream from the interstitial fluid of the brain. In addition, the diagnostic performance of TBI biomarkers is affected by sampling timing and analytical methods. In this focused review, the clinical aspects of glial fibrillary acidic protein, neurofilament light, S100 calcium-binding protein B, tau and ubiquitin C-terminal hydrolase-L1 are examined. Current findings and clinical caveats are addressed.
Turun yliopiston Tutkimustietojärjestelmän portaali